SEMITrends Survey, on behalf of the EAU Testicular Cancer Guidelines Panel

SEMITrends Survey

The updated IGCCG classification indicated the presence of raised LDH over the cut-off of x2.5 ULN (upper limit of normal) as a prognostic factor for poorer survival in good risk-seminoma tumours. The retrospective analysis of survival outcomes in the modern era based on this criterion indicated that high-LDH good risk patients have a progression-free survival and overall survival that are similar to these of intermediate risk patients, and distinct from the low-LDH good risk patients.
We aim to assess the current real-life management trends amongst European oncologists that treat metastatic seminoma in the light of the updated IGCCCG classification on seminomas.
References:
  • Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg CN, Vaughn DJ, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S; International Germ Cell Cancer Classification Update Consortium. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol. 2021 May 10;39(14):1553-1562. doi: 10.1200/JCO.20.03292. Epub 2021 Mar 17. PMID: 33729863; PMCID: PMC8099394.
  • Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer C, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D, European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol. 2023 84(3): 289-301, ISSN 0302-2838, https://doi.org/10.1016/j.eururo.2023.04.010.
1.Are you taking in consideration the updated IGCCCG classification of good-risk seminoma when you discuss treatment options with patients?
2.How do you currently treat high-LDH good-risk seminomas?
3.Would you be interested in participating in a randomised clinical trial looking into an optimisation strategy for high-LDH good risk seminoma?
4.What percentage of your clinical practice is dedicated to testicular cancer patients?
5.How many good-risk metastatic seminoma patients do you treat with chemotherapy annually?
6.You clinical practice setting:
7.Your specialty:
8.Your country of clinical practice:
Current Progress,
0 of 8 answered